This company listing is no longer active
ONPP.F Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.27 |
| 52 Week High | SEK 0.60 |
| 52 Week Low | SEK 0.27 |
| Beta | -0.32 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -97.62% |
| 5 Year Change | n/a |
| Change since IPO | -98.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONPP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -7.7% | 1.2% |
| 1Y | n/a | -13.5% | 7.7% |
Return vs Industry: Insufficient data to determine how ONPP.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ONPP.F performed against the US Market.
Price Volatility
| ONPP.F volatility | |
|---|---|
| ONPP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ONPP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ONPP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 62 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors.
Oncopeptides AB (publ) Fundamentals Summary
| ONPP.F fundamental statistics | |
|---|---|
| Market cap | US$48.52m |
| Earnings (TTM) | -US$22.95m |
| Revenue (TTM) | US$3.66m |
13.3x
P/S Ratio-2.1x
P/E RatioIs ONPP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONPP.F income statement (TTM) | |
|---|---|
| Revenue | SEK 39.17m |
| Cost of Revenue | -SEK 803.00k |
| Gross Profit | SEK 39.97m |
| Other Expenses | SEK 285.76m |
| Earnings | -SEK 245.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 14, 2024
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 102.05% |
| Net Profit Margin | -627.53% |
| Debt/Equity Ratio | -1,348.4% |
How did ONPP.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/31 21:34 |
| End of Day Share Price | 2024/05/03 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncopeptides AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Peter Welford | Jefferies LLC |